Cognitive late effects are among the most common lifealtering sequelae of childhood
cancer, with reported prevalence ranging from 35% to 60% depending on specific …

PURPOSE Despite contemporary treatment, up to 10% of children with acute lymphoblastic
leukemia still experience relapse. We evaluated whether a higher dosage of PEG …

A new era of treatment for childhood cancer has welcomed an increasing number of long-
term survivors, for whom acute and late neurologic and neurocognitive sequelae related to …

Background Socioeconomic status (SES) is a determinant of cognitive and academic
functioning among healthy and ill children; however, few pediatric oncology studies examine …

Neurotoxicity associated with CAR-T cell therapy can be life-threatening. With rapid
development of CAR-T therapies, a systematic method is needed to identify and monitor …

Background The purpose was to examine associations between treatment and chronic
health conditions with neurocognitive impairment survivors of acute lymphoblastic leukemia …

PURPOSE Findings from St Jude Total Therapy Study 16 (Total 16) showed early
intensification of triple intrathecal therapy (ITT) improved CNS disease control for children …

Objective Children with acute lymphoblastic leukemia (ALL) are at risk for neurocognitive
deficits, and examining individual variability is essential to understand these risks. This study …

Background Acute lymphoblastic leukemia (ALL) is the most common malignancy in
children, and methotrexate (MTX) is the key drug for ALL. Studies on the relationship …

Purpose Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer
diagnosis. Cognitive late effects develop in 20%–40% of ALL survivors, but the course of …